Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.
Clin Interv Aging. 2009;4:379-89. doi: 10.2147/cia.s5242. Epub 2009 Oct 12.
Hypertension in the elderly is associated with increased occurrence rates of sodium sensitivity, isolated systolic hypertension, and 'white coat effect'. Arterial stiffness and endothelial dysfunction also increase with age. These factors should be considered in selecting antihypertensive therapy. The prime objective of this therapy is to prevent stroke. The findings of controlled trials show that there should be no cut-off age for treatment. A holistic program for controlling cardiovascular risks should be fully discussed with the patient, including evaluation to exclude underlying causes of secondary hypertension, and implementation of lifestyle measures. The choice of antihypertensive drug therapy is influenced by concomitant disease and previous medication history, but will typically include a thiazide diuretic as the first-line agent; to this will be added an angiotensin inhibitor and/or a calcium channel blocker. Beta blockers are not generally recommended, in part because they do not combat the effects of increased arterial stiffness. The hypertension-hypotension syndrome requires case-specific management. Drug-resistant hypertension is important to differentiate from faulty compliance with medication. Patients resistant to third-line drug therapy may benefit from treatment with extended-release isosorbide mononitrate. A trial of spironolactone may also be worthwhile.
老年人高血压与钠敏感性、单纯收缩期高血压和“白大衣效应”的发生率增加有关。动脉僵硬和内皮功能障碍也随年龄增长而增加。在选择抗高血压治疗时应考虑这些因素。该治疗的主要目的是预防中风。对照试验的结果表明,治疗不应有年龄限制。应与患者充分讨论控制心血管风险的整体方案,包括评估是否存在继发性高血压的潜在原因,以及实施生活方式措施。抗高血压药物治疗的选择受伴发疾病和既往用药史的影响,但通常包括噻嗪类利尿剂作为一线药物;在此基础上,还会添加血管紧张素抑制剂和/或钙通道阻滞剂。一般不建议使用β受体阻滞剂,部分原因是它们不能对抗动脉僵硬增加的影响。高血压-低血压综合征需要根据具体情况进行管理。药物抵抗性高血压重要的是要与药物治疗的依从性差相区别。对三线药物治疗有抵抗的患者可能受益于延长释放单硝酸异山梨酯的治疗。螺内酯的试验也可能是值得的。